HLA-B27 structure, function, and disease association

Current Opinion in Rheumatology

Volumn 8, Issue 4, 1996, Pages 296-308

  López Larrea, Carlos ^a   Gonzalez Roces, Severino ^a   Alvarez, Victoria ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B27 ANTIGEN;

ALLELE; ANKYLOSING SPONDYLITIS; ANTIGEN PRESENTATION; DISEASE ASSOCIATION; HLA SYSTEM; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SPONDYLOARTHROPATHY;

EID: 0029737948     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199607000-00005     Document Type: Review

References (96)

1. Breuning MH, Lucas CJ, Breur BS: Subtypes of HLA-B27 detected cytotoxic T lymphocytes and their role in self-recognition. Hum Immunol 1982, 5:259-268.
2. Choo SY, Antonelli P, Nisperos B, Nepom GT, Hansen JA: Six variants of HLA-B27 identified by isoelectric-focusing. Immunogenetics 1986, 23:24-29.
3. Dominguez O, Coto E, Martinez-Naves E, Choo SY, López-Larrea C: Molecular typing of HLA-B27 alleles. Immunogenetics 1992, 36:277-282.
4. Reekers P, Tiilikainen A, Darke C, van der Horst A, McCloskey D: HLA-B7 like antigens [B703 (BPOT), B7Qui, BDT, B7SL, B7X40, BRI, B41V]. In HLA 1991. Edited by Tsuji K, Aziwa M, Sasazuki T. Oxford: Oxford University Press; 1992:327-330.
5. López de Castro JA: HLA-B27 and HLA-A2 subtypes: structure, evolution and function. Immunol Today 1989, 10:239-246.
6. Choo SY, Fan L-A, Hansen JA: A novel HLA-B27 allele maps B27 allospecificity to the region around position 70 in the alpha 1 domain. J Immunol 1991, 147:174-180.
7. Vilches C, de Pablo R, Kreisler M: Nucleotide sequence of HLA-B*2706. Immunogenetics 1994, 39:219.
8. Hildebrand WH, Domena JD, Shen SY, Marsh S, Bunce M, Guttridge MG, Darke C, Parham P: The HLA-B7Qui antigen is encoded by a new subtype of HLA-B27 (B*2708). Tissue Antigens 1994, 44:47-51.
9. Del Porto P, D'Amato M, Fiorillo MT, Tuosto L, Picolella E, Sorrentino R: Identification of a novel HLA-B27 subtype by restriction analysis of a citotoxic gamma delta T cell clone. J Immunol 1994, 153:3093-30100.
10. Rudwaleit M, Bowness P, Wordsworth P: The nucleotide sequence of HLA-B*2704 reveals a new amino acid substitution in exon 4 which is also present in HLA-B*2706. Immunogenetics 1996, 43:160-162.
11. Parham P, Lomen CE, Lawlor DA, Ways JP, Holmes N, Coppin HL, Salter RD, Wan AM, Ennis PD: Nature of polymorphism in HLA-A, -B and -C molecules. Proc Natl Acad Sci U S A 1988, 85:4005-4009.
12. López de Castro JA: Structural polymorphism and function of HLA-B27. Curr Opin Rheumatol 1995, 7:270-278. Important overview of the present knowledge on the molecular structure and function of HLA-B27. Very useful in illustrating the pathogenic role that the peptide-binding properties of HLA-B27 can play in the development of SpA.
13. Khan MA: HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 1995, 7:263-269. This review compiles relevant information of the distribution of B27 and its subtypes in world populations.
14. López-Larrea C, Sujirachato K, Mehra NK, Chiewslip P, Isarangkura D, Kanga U, Dominguez O, Coto E, Peǹa M, Setién F, González-Roces S: HLA-B27 subtypes in Asian patients with ankylosing spondylitis: evidence for new associations. Tissue Antigens 1995, 45:169-176. Subtypes of B27 were investigated in two groups of healthy (n = 17) and AS patients (n = 45) from Asian Indian and Thai populations. B*2706 was found in 47% of the healthy Thai individuals and was absent in patients. The negative association described suggests a protective effect of this subtype on AS susceptibility in Thai patients. B*2707 was found to be associated with AS in the populations studied.
15. González-Roces S, Brautbar C, Peña M, Dominguez O, Coto E, Alvarez V, Segal R, López-Larrea C: Molecular analysis of HLA-B27 haplotypes in Caucasoids: frequencies of B27-Cw in Jewish and Spanish populations. Hum Immunol 1994, 41:127-134.
16. Parham P, Arnett KL, Adams EJ, Barber LD, Domena JD, Stewart D, Hildebrand WH, Little AM: The HLA-B73 antigen has a most unusual structure that defines a second lineage of HLA-B alleles. Tissue Antigens 1994, 43:302-313.
17. Madden DR, Gorga JC, Strominger JL, Wiley DC: The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 1991, 353:321-325.
18. Madden DR, Gorga JC, Strominger JL, Wiley DC: The three-dimensional structure of HLA-B27 at 2,1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992, 70:1035-1048.
19. Rammensee HG: Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 1995, 7:85-96. Reviews the progress that has been made in understanding how MHC molecules bind peptides. This structural information on the peptide-binding receptor has been complemented by the identification of the sequences of the peptides that are naturally bound to MHC molecules.
20. Rammensee HG, Friede T, Stevanovic S: MHC ligands and peptide motifs: first listing. Immunogenetics 1995, 41:178-228.
21. Urban RG, Chicz RM, Lane WS, Strominger JL, Rehm A, Keuter MJ, UytdeHaag FG, Ploegh H, Uchnska-Ziegler B, Ziegler A: A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc Natl Acad Sci U S A 1994, 91:1534-1538.
22. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC: Identification of self peptides bound to purified HLA-B27. Nature 1991, 353:326-329.
23. Parker KC, Biddison WE, Coligan JE: Pocket mutations of HLA B27 show that anchor residues act cumulatively to stabilize peptide binding. Biochemistry 1994, 33:7736-7743.
24. Feltkamp TEW, Khan MA, López de Castro JA: The pathogenetic role of HLA-B27. Immunol Today 1996, 17:5-7.
25. Tanigaki N, Fruci D, Vigneti E, Starace G, Rovero P, Loudel M, Butler RH, Tosi R: The peptide binding specificity of HLA-B27 subtypes. Immunogenetics 1994, 40:192-198.
26. Rötzschke O, Falk K, Stevanovic S, Gnau V, Jung G, Rammensee HG: Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs. Immunogenetics 1994, 39:74-77.
27. Rovero P, Riganelli D, Fruci D, Vigano S, Pegoraro S, Revoltella R, Greco G, Butler R, Clementi S, Tanikagi N: The importance of secondary anchor residue motifs of HLA class I proteins: a chemometric approach. Mol Immunol 1994, 31:549-554.
28. Colbert RA, Rowland-Jones SL, McMichael AJ, Fretinger JA: Differences in peptide presentation between B27 subtypes: the importance of the P1 side chain in maintaining high affinity peptide binding to B*2703. Immunity 1994, 1:1-20.
29. Fruci D, Butler RH, Greco G, Rovero P, Pazmany L, Vigneti E, Tosi R, Tanikagi N: Differences in peptide-binding specificity of two ankylosing spondylitls-associated HLA-B27 subtypes. Immunogenetics 1995, 42:123-128. Binding of polyalanine-derived nonapeptides carrying Arg at P2 and a different amino acid at P9 by B*2705 and B*2702 were analyzed. Peptides with basic residues, aliphatic and aromatic at P9, have similar affinity in the binding of B*2705. However, B*2702 binds well to P9 aliphatic and aromatic peptides but only very weakly to basic peptides. Substitution at position 81 can explain the differences for both B*2702- and B*2705-bound peptides.
30. Rognan D, Scapozza L, Folkers G, Daser A: Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigen. Proc Natl Acad Sci U S A 1995, 92:753-757. A molecular dynamic simulation method based on the MHC-ligand complex was used to predict the role of secondary anchor residues for binding to B27. Several nonnatural peptides were designed to optimize the P3 interactions with pocket D, showing that a bulky hydrophobic side chain at P3 enhances the binding to HLA-B27, Furthermore, the putative TCR contact (P4-P8) was replaced with organic fragment without altering the affinity of this designed ligand. The combination of these strategies opens new possibilities for designing peptides for use in immunotherapy.
31. Rovero P, Vigano S, Pegorado S: Augmentation of the affinity of HLA class I-binding peptides lacking primary anchor residues by manipulation of the secondary anchor residues. J Pept Sci 1995, 1:266-273.
32. Villadangos JA, Galocha B, Garcia F, Albar JJP, López de Castro JA: Modulation of peptide binding by HLA-B27 polymorphism in pockets A and B, and peptide specificity of B*2703. Eur J Immunol 1995, 25:2370-2377. The contribution of major anchor residues 2 and 9, the role of pocket B structure, and the binding properties of B*2703 were analyzed. Synthetic peptides presented by B*2705 demonstrated that Arg2 is not absolutely required because Gln2 analogues also bind. Changes affecting positions 2 and 9 suggested that B*2703 is probably the most stringent specificity for the Arg2 peptide motif. The binding dependence of the B*2703 subtype can be explained by the molecular effect of the His59 change.
33. Wen J, Wang J, Kuipers JG, Huang F, Williams KM, Raybourne RB, Yu DT: Analysis of HLA-B*2705 peptide motif, using T2 cells and monoclonal antibody ME1. Immunogenetics 1994, 39:444-446.
34. Rognan D, Scapozza L, Folkers G, Dasser A: Molecular dynamics simulation of MHC-peptide complex as a tool for predicting potential T cell epitopes. Biochemistry 1994, 33:11476-11485.
35. Bowness P, Allen RL, McMichael AJ: Identification of T cell receptor recognition residues for a viral peptide presented by HLA-B27. Eur J Immunol 1994, 24:2357-2363.
36. Kellner H, Wen J, Wang J, Raybourne RB, Williams KM, Yu DT: Serum antibodies from patients with ankylosing spondylitis and Reiter's syndrome are reactive with HLA-B27 cells transfected with the Mycobacterium tuberculosis hsp60 gene. Infect Immun 1994, 62:484-491.
37. Huang F, Hermann E, Wang J, Cheng X-K, Tsai Weh, Wen J, Kuipers JG, Kellner H, Ackermann B, Roth G, Williams KM, Tak D, Yu Y, Raybourne RB: A patient-derived cytotoxic T-lymphocyte clone and two peptidedependent monoclonal antibodies recognize HLA-B27-peptide complexes with low stringency for peptide sequences. Infect Immun 1996, 64:120-127.
38. Fukazawa T, Wang J, Huang F, Wen J, Tyan D, Williams KM, Raybourne RB, Yu DT: Testing the importance of each residue in a HLA B27-binding peptide using monoclonal antibodies. J Immunol 1994, 152:1190-1196.
39. Fukazawa T, Hermann E, Edidin M, Wen J, Huang F, Kellner H, Floege J, Farahmandian D, Williams Km, Yu Dt: The effect of mutant β2-microglobulins on the conformation of HLA-B27 detected by antibody and by cytotoxic T lymphocytes. J Immunol 1994, 153:3543-3550.
40. Tussey LG, Rowland-Jones S, Zheng TS, Androlewicz MJ, Cresswell P, Frelinger JA, McMichael AJ: Different MHC class I alleles compete for presentation of overlapping viral epitopes. Immunity 1995, 3:65-77. Coexpression in NW lymphoblastoid cells of B8 and B*2702 prevented the presentation on HLA-B8 influenza A nucleoprotein-restricted epitope by HLA-B8, although added peptide could still be presented. The results suggest competition mechanisms occurring between the two class I molecules in the endoplasmic reticulum.
41. Huet S, Nixon DF, Rothbard JB: Structural homologies between two HLA-B27 restricted peptides suggest residues important for interaction with HLA-B27. Int Immunol 1990, 2:311-316.
42. Brooks JM, Murray RJ, Thomas WA, Kurilla MG, Rickinsom AB: Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J Exp Med 1993, 178:879-887.
43. Cerrone MC, Ma JJ, Stephens RS: Cloning and sequence for the heat-shock protein-60 from Chlamydia trachomatis and immunological reactivity of the protein. Infect Immun 1991, 59:79-80.
44. van Binnendijk RS, Versteeg van Oosten JPM, Poelen MCM, Brugghe HF, Hoogerhont P, Osterhans AD, Uytdehaag FG: Human class I and class II-restricted cloned cytotoxic lymphocytes identify a cluster of epitopes on the measles virus fusion protein. J Virol 1993, 67:2276-2284.
45. Gao XM, Wordsworth P, McMichael AJ: Collagen-specific cytotoxic T lymphocyte responses in patients with ankylosing spondylitis and reactive arthritis. Eur J Immunol 1994, 24:1665-1670.
46. Rötzschke O, Falk K, Faath S, Rammensee HG: On the nature of peptides involved in T-cell alloreactivity. J Exp Med 1991, 174:1059-1071.
47. Löpez D, Barber DF, Villadangos JA, Löpez de Castro JA: Cross-reactive T-cell clones from unrelated individuals reveal similarities in peptide presentation between HLA-B27 and HLA-DR2. J Immunol 1993, 150:2675-2686.
48. Villadangos JA, Galocha B, Garcla-Hoyo R, Lopez D, Garcia F, López de Castro JA: Structure of HLA-B27-specific T cell epitopes: antigen presentation in B*2703 is limited mostly to a subset of the antigenic determinants on B*2705. Eur J Immunol 1994, 24:2548-2555.
49. López D, Garcia-Hoyo R, López de Castro JA: Clonal analysis of alloreactive T cell responses against the closely related B*2705 and B*2703 subtypes. J Immunol 1994, 152:5557-5571.
50. Barber D, López D, López de Castro JA: T-cell receptor diversity in alloreactive responses against HLA-B27 (B*2705) is limited by multiple-level restrictions in both α and β chains. Eur J Immunol 1995, 25:2479-2485. An analysis of TCRs in HLA-B27 (B*2705) alloreactivity was carried out in CTLs from two individuals. Both α and β chain usage was nonrandom, but there were significant differences. Preferential Vα usage was associated with particular individuals. In contrast, preferred usage of Vβ subgroup 4 was a major donor- and epitope-independent feature, suggesting an involvement in the recognition of the HLA-B27 molecule.
51. Duchmann R, May E, Ackermann B, Goergen B, Meyer Zum Büschenfelde K-H, Märker-Hermann E: HLA-B27-restricted cytotoxic T lymphocyte responses to arthritogenic enterobacteria or self antigens are dominated by closely related TCRBV gene segment: a study in patients with reactive arthritis. Scand J Immunol 1996, 43:101-108.
52. Callan MFC, Reyburn HT, Bowness P, Rowland-Jones S, Bell JI, McMichael AJ: Selection of T-cell receptor variable gene encoded amino acids on the third binding site loop: a factor influencing variable chain selection in a T-cell response. Eur J Immunol 1995, 25:1529-1534.
53. MacLean IL: HLA-B27 subtypes: implications for the spondyloarthropathies. Ann Rheum Dis 1992, 51:929-931.
54. D'Amato M, Fiorillo MT, Carcassi C, Mathieu A, Zucarelli A, Bitti PP, Tosi R, Sorrentino R: Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995, 25:3199-3201. Subtypes of HLA-B27 were analyzed in groups of 40 healthy individuals and 35 Sardinian AS patients. B*2709 accounts for 25% of the HLA-B27 subtypes in this population. None of the patients were found to be positive. B*2709 differs from the widespread AS-associated B*2705 allele for a single substitution (His vs Asp) that can be relevant in AS susceptibility.
55. Barber LD, Gillece-Castro B, Percival L, Li X, Clayberger C, Parham P: Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes. Curr Biol 1995, 5:179-190.
56. Fiorillo MT, Greco G, Sorrentino R: The Asp116-His116 substitution in a novel HLA-B27 subtype influences the acceptance of the peptide C-terminal anchor. Immunogenetics 1995, 41:38-39. Describes the construction of model peptides that differ only at P9. The binding of these peptides to B*2705 and B*2709 were compared. Two amino acids are accepted by B*2705 and not by B*2709: Arg and Tyr. Thus the 116 position seems to influence the amino acids accepted at P9.
57. Fruci D, Greco G, Vigneti E, Tanikagi N, Butler RH, Tosi R: The peptide binding specificity of HLA-B27 subtype (B*2705) analyzed by the use of polyalanine model peptides. Hum Immunol 1994, 41:34.
58. Huczko EL, Bodnar WM, Benjamin D, Sakaguchi K, Zhu NZ, Shabanowita J, Henderson RA, Appella E, Hunt DF, Engelhard VH: Characteristic of endogenous peptides eluted from the class I MHC molecule HLA-B7 determined by mass spectrometry and computer modeling. J Immunol 1993, 151:2572-2587.
59. Sette A, Vitiello A, Reherman B, Fowler P, Nayersima R, Martin Kast W, Melief CJM, Oseroff C, Yuan L, Ruppert J, et al.: The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994, 153:5586-5592.
60. Rojo S, Garcia F, Villadangos JA, López de Castro JA: Changes in the repertoire of peptides bound to HLA-B27 subtypes and to site-specific mutants inside and outside pockets B. J Exp Med 1993, 177:613-620.
61. Järvinen P: Occurrence of ankylosing spondylitis in a nationwide series of twins. Arthritis Rheum 1995, 38:381-383.
62. Robinson WP, van der Linden SM, Khan MA, Rentch HU, Cats A, Russell A, Thomson G: HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B27+ patients. Arthritis Rheum 1989, 32:1135-1141.
63. Rubin LA, Amos CI, Wade JA, Martin JR, Bale SJ, Little AH, Gladman DD, Banney GE, Rubenstein JD, Siminovitch KA: Investigating the genetic basis for ankylosing spondylitis: linkage studies with the major histocompatibility complex region. Arthritis Rheum 1994, 37:1212.
64. Monowarul Islam SM, Numaga J, Fujino Y, Masuda K, Ohda H, Hirata R, Maeda H, Mitsui H: HLA-DR8 and acute anterior uveitis in ankylosing spondylitis. Arthritis Rheum 1995, 38:547-550.
65. Yamaguchi A, Tsuchiya N, Mitsui H, Shiota M, Ogawa A, Tokunaga K, Yoshinoya S, Juji T, Ito K: Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Arthritis Rheum 1995, 38:1672-1677.
66. Maksymowych WP, Tao S, Li Y, Wing M, Russell AS: Allelic variation at the TAP1 locus influences disease phenotype in HLA-B27 positive individuals with ankylosing spondylitis. Tissue Antigens 1995, 45:328-332.
67. Barron KS, Reveille JD, Carrington M, Mann DL, Robinson MA: Susceptibility to Reiter's syndrome is associated with alleles of TAP genes. Arthritis Rheum 1995, 38:684-689.
68. Westman P, Partanen J, Leirisalo-Repo M, Koskimies S: TAP1 and TAP2 polymorphism in HLA-B27-positive populations: no allelic differences in ankylosing spondylitis and reactive arthritis. Human Immunol 1995, 44:236-242.
69. Maksymowych WP, Wessler A, Schmitt.Egenolf M, Suarez-Almazor M, Ritzel G, Von Borstel RC, Pazderka F, Russell AS: Polymorphism in an HLA linked proteasome gene influences phenotypic expression of disease in HLA-B27-positive individuals. J Rheumatol 1994, 21:665-669.
70. Ploski R, Flato B, Vinje O, Maksymowych W, Forre O, Thorsby E: Association to HLA-DRB1·08, HLA-DPB1·0301 and homozygosity for an HLA-linked proteasome gene in juvenile ankylosing spondylitis. Hum Immunol 1995, 44:88-96.
71. Kingsley G, Sieper J: Current perspectives in reactive arthritis. Immunol Today 1993, 14:387-391.
72. Burmester GR, Daser A, Kamradt T, Krause A, Mitchison NA, Sieper J, Wolf N: Immunology of reactive arthritides. Annu Rev Immunol 1995, 13:229-250. This excellent review describes in detail the progress made during the past few years in defining the immunologic basis as well as epidemiologic findings relevant to the chronicity of reactive arthritides.
73. Kingsley G, Panayi GS: Antigenic responses in reactive arthritis. Rheum Dis Clin North Am 1992, 18:49-66.
74. Hermann E, Sucke B, Droste U, Meyer zum Büschenfelde: Klebsiella pneumoniae-reactive T cells in blood and synovial fluid of patients with ankylosing spondylitis. Arthritis Rheum 1995, 38:1277-1282. This work describes reduction of K. pneumoniae-responsive T cells in the peripheral blood of AS patients compared with healthy HLA-B27-positive controls. This finding may reflect a defective peripheral T cell response to Klebsiella in B27-positive patients.
75. Baum H, Davies H, Peakman M: Molecular mimicry in the MHC: hidden clues to autoimmunity? Immunol Today 1996, 17:64-70.
76. Sieper J, Braun J: Pathogenesis of spondylarthropathies: persistent bacterial antigen, autoimmunity, or both? Arthritis Rheum 1995, 38:1547-1554. A critical review that summarizes different hypotheses related to explanations of B27 and pathogenesis of SpA. Evidence for and and against the possible mechanisms involved is discussed.
77. Hermann E: Enterobacterial antigens with tropism for joint structures and HLA-B27-restricted cytotoxic T-cells in reactive arthritis. Scand J Rheumatol 1995, 24(suppl 101):203-206.
78. Braum J, Bollow M, Neure L, Seipelt E, Seyrekbason F, Herbst H, Eggens U, Distler A, Sieper J: Use of immunohistologic and in situ hybridization techniques in the examination of sacroliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995, 38:499-505.
79. Skurnik M, Batsford S, Mertz A, Schiltz E, Toivanen P: The putative arthritogenic cationic 19-kilodalton antigen of Yersinia enterocolitica is a urease β-subunit. Infect Immun 1993, 61:2498-24504.
80. Deane K, Jeacock R, Hassell A, Pearce J, Gaston JSH: Identification of two target antigens recognized by synovial fluid T cells in Chlamydiainduced reactive arthritis [Abstract]. Arthritis Rheum 1994, 37(suppl 9):367.
81. Mertz A, Daser A, Skurnik M, Wiesmüller K-H, Braun J, Appel H, Bratford S, Wu P, Distler A, Sieper J: The evolutionary conserved ribosomal protein L23 and the cationic urease β-subunit of Yersinia enterocolitica 0:3 belong to the immunodominant antigens in Yersinia-triggered reactive arthritis: implications for autoimmunity. Mol Med 1994, 1:44-55.
82. Daser A, Urlaub H, Henklein P: HLA-B27 binding peptides derived from the 57Kd heat shock protein of Chlamydia trachomatis: novel insights into the peptide binding rules. Mol Immunol 1994, 31:331-336.
83. Scofield RH, Warren WL, Gross T, Warren WL, Harley JB: HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet 1995, 345:1542-1544. Several short peptide sequences are shared between the first hypervariable region of B27 and proteins of gram-negative bacteria. The B*2705 sequence contains a nonapeptide, LRRYLENGK, predicted to bind in the binding cleft of B27. Some nonapeptides from enteric bacteria that share sequence with B27 were tested for binding by B27 with an assembly assay. Thus peptides that both mimic and bind B27 may constitute the molecular components of the mechanism of spondyloarthropathies.
84. Stieglitz H, Lipsky P: Association between reactive arthritis and antecedent infection with Shigella flexneri carrying a 2-Md plasmid and encoding an HLA-B27 epitope. Arthritis Rheum 1993, 36:1387-1391.
85. Wildner G, Thurau SR: Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: a clue to major histocompatibility complex association with autoimmune disease. Eur J Immunol 1994, 24:2579-2585.
86. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL: Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993, 178:27-47.
87. Schwimmbeck PL, Yu DTY, Oldsone MBA: Autoantibodies to HLA-B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome: molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med 1987, 166:173-181.
88. Lahesmaa R, Skurnik M, Granfors K, Mottonen T, Saaria R, Toivanen P: A tetrapeptide shared by Yersinia outer membrane protein YOP1 and HLA-B27: antibody response in patients with Yersinia-induced reactive arthritis. Scand J Rheumatol 1990, 88(suppl):70-71.
89. Stieglitz H, Fosmire S, Lipsky P: Identification of a 2-Md plasmid from Shigella flexneri associated with reactive arthritis. Arthritis Rheum 1990, 32:937-946.
90. Fielder M, Pirt SJ, Tarpey I, Wilson C, Cunningham P, Ettelaie C, Binder A, Bansal S, Ebringer A: Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulanase of Klebsiella pneumoniae. FEBS Lett 1995, 369:243-248. In this study a computer search has revealed a novel homology between pulD K. pneumoniae secretion protein and B*2705. Additionally, molecular mimicry has been described between pullulanase enzyme (pul A) and types I, II, and III collagen. Furthermore, the level of cross-reactive antibodies found in AS patients could be relevant in the development of the disease.
91. Hammer RE, Maika SD, Richardson JA, Tang J-P, Taurog JD: Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2-m: an animal model of HLA-B27-associated human disorders. Cell 1990, 63:1099-1112.
92. Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE: Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of expression. J Immunol 1993, 150:4168-4178.
93. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernándes-Sueiro JL, Balish E, Hammer RE: The germ free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994, 180:2359-2364.
94. Weinreich S, Eulderink F, Capkova J, Pla M, Gaede K, Heesemann J, van Alphen L, Zurcher C, Hoebe-Hewryk B, Kievits F, Ivanyi P: HLA-B27 as a relative risk factor in ankylosing enthesopathy in transgenic mice. Hum Immunol 1995, 42:103-115. This paper describes the macroscopic and histologic features in a new model of transgenic mice, naturally occurring joint disease or ankylosing enthesopathy. The frequency of ankylosing enthesopathy is dependent on the H-2 type and the presence of HLA-B27. Its relation to age, gender, environment, and immunology is considered.
95. Weinreich S, Hoebe B, Ivanyi P: Maternal age influences risk for HLA-B27 associated ankylosing enthesopathy in transgenic mice. Ann Rheum Dis 1995, 54:754-756.
96. 4 T cell.